Eli Lilly & Company OPEB

Eli Lilly & Company OPEB

Eli Lilly & Company OPEB is the trust that funds other post-employment benefits — primarily health insurance — for retirees of the pharmaceutical manufacturer. The plan operates out of Indianapolis, where Eli Lilly and Company has been headquartered since its founding in 1876. Susan Ridlen served as Chief Investment Officer and Assistant Treasurer for the trust until 2025, managing the vehicle's long-duration liability-matching mandate over a tenure that spanned more than 20 years. Jane A. Kirkham serves as a Fund Advisory Committee Delegate, providing governance oversight. The disclosed investment posture is concentrated in growth capital, a mandate that can span equity co-investments, private credit, and directly originated opportunities targeting capital appreciation. Reported holdings include trust-owned life insurance (TOLI) contracts, a structure corporate OPEB plans sometimes use to prefund retiree health obligations with tax-advantaged insurance vehicles. While the trust does not publicly disclose its full portfolio, corporate filings and plan documents consistently classify it as a health plan trust rather than a general pension fund — meaning its liability profile skews toward healthcare inflation sensitivity and shorter actuarial durations than a defined-benefit retirement plan. The trust benefits from its proximity to the broader Lilly ecosystem. Eli Lilly and Company ranks among the world's largest pharmaceutical firms by market capitalization, a position supercharged by its dominant GLP-1 drug portfolio. The Lilly Endowment Inc. — a separate philanthropic foundation with deep historical ties to the Lilly family and company — operates independently but shares a corporate lineage. That network provides adjacent institutional context, though the OPEB trust maintains its own governance and investment advisory structures. The plan's defining structural feature is its employer-backed OPEB trust construction. Unlike retiree health obligations that sit on a corporate balance sheet as an unfunded liability, Eli Lilly elected to prefund its obligation through a dedicated trust with segregated assets and independent fiduciary oversight. That architecture insulates the benefit pool from the sponsor's operating risk while creating a distinct investment entity with its own allocation committee.